Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

5:00 PM ET 8-K
Financial Results Evofem Biosciences, Inc. EVFM

Evofem Biosciences Financial Results

Evofem Biosciences reported Q3 2026 financial results, achieving $0.7 million in operating income despite a slight decline in net sales to $4.6 million. The company highlighted the shipment of its 500,000th box of PHEXX and the addition of a fifth study site for an NIH-funded Phase 4 trial of SOLOSEC.

Term
Q3 2026

“While third quarter net sales reflect the cumulative impact of operating without dedicated growth capital for brand promotion and physician outreach since late 2022, we are proud of the discipline, efficiency and tenacity demonstrated across the organization. Through rigorous expense management, we generated $0.7 million of operating income during the quarter while continuing to support patients and healthcare providers who rely on our innovative sexual health products.”

Saundra Pelletier, CEO of Evofem
5:00 PM ET 8-K
Other 8-K Filing byNordic Acquisition Corp BYNO

byNordic Acquisition Other 8-K Filing

byNordic Acquisition Corp deposited $8,850.20 into its trust account to extend the deadline for completing its initial business combination by one month. The extension moves the termination date from November 12, 2026, to December 12, 2026, and represents the fourth of twelve possible monthly extensions.

Term
1 month
4:59 PM ET 10-Q
Financial Results BioScience Health Innovations, Inc. BHIC

BioScience Health Innovations Q3 2026 Results: Net Loss of $149K, Loss Widens

BioScience Health Innovations, Inc. reported a net loss of $564,885 for the nine months ended September 30, 2026, a significant decline from the $875,720 net income in the prior year period. Despite the loss, the company successfully raised over $2 million through common stock sales, ending the period with a strengthened cash position of $1,691,858.

Key figure
Net loss $149K
4:58 PM ET 10-Q
Financial Results KKR Private Equity Conglomerate LLC

KKR Private Equity Conglomerate Q3 2026 Results: Net Income $351M, Up 12.4% YoY

KKR Private Equity Conglomerate LLC reported a net increase in net assets resulting from operations of $975.5 million for the nine months ended September 30, 2026, compared to $762.1 million in the prior year period. Total assets grew to $13.6 billion, driven by a significant increase in investments at fair value and cash holdings.

Key figure
Net income $351M · +12.4% YoY
4:58 PM ET 10-Q
Financial Results Evofem Biosciences, Inc. EVFM

Evofem Biosciences Q3 2026 Results: Turns Profitable, Net Income $1M

Evofem Biosciences reported a significant decline in total assets from $20.3 million at year-end 2025 to $7.3 million as of September 30, 2026, driven largely by a decrease in trade accounts receivable and intangible assets. The company faces substantial liquidity challenges with $84.8 million in current liabilities and has received notices of default from Future Pak, LLC regarding its debt obligations.

Key figure
Net income $1M
4:56 PM ET 10-Q
Financial Results Senior Credit Investments, LLC

Senior Credit Investments Q3 2026 Results: Net Income $6.96M, Up 68.5% YoY

Senior Credit Investments, LLC reported a net increase in member’s capital resulting from operations of $18.4 million for the nine months ended September 30, 2026, up from $12.0 million in the prior year period. Total investment income grew significantly to $40.4 million, driven by interest income from its non-controlled/non-affiliated investment portfolio, while net asset value per unit decreased slightly to $1,767.94 from $1,787.98 at year-end 2025.

Key figure
Net income $6.96M · +68.5% YoY
4:56 PM ET 10-Q
Financial Results Jefferies Credit Partners BDC Inc.

Jefferies Credit Partners BDC Q3 2026 Results: Net Income $20.9M, Up 73.5% YoY

Jefferies Credit Partners BDC Inc. reported a net increase in net assets resulting from operations of $52.0 million for the nine months ended September 30, 2026, compared to $30.5 million for the same period in 2025. Total net assets grew to $964.9 million from $677.0 million at year-end 2025, driven by significant capital share issuances and investment income growth.

Key figure
Net income $20.9M · +73.5% YoY
4:56 PM ET 10-Q
Financial Results 21Shares Solana Staking ETF TSOL

21Shares Solana Staking ETF Q3 2026 Results: Net Income $2.23M

The 21Shares Solana Staking ETF reported net assets of $9,786,070 as of September 30, 2026, a significant increase from $5,735,019 at the end of 2025. The Trust generated $102,143 in staking rewards for the nine months ended September 30, 2026, and transitioned its pricing benchmark to the FTSE Solana Index in August 2026.

Key figure
Net income $2.23M
4:55 PM ET Form 4
Insider Selling Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Director Laura Brege Sells $1.33M of Stock

Laura Brege, Director, sold 14,167 shares of Mirum Pharmaceuticals, Inc. at $94.05 to $94.74 a share (average $94.21) in 2 transactions, worth $1.33M in total on Nov 11, 2026. Shares held after the trade: 15,703 (-17.2%).

Value
$1.33M
Shares
14,167
Average price
$94.21
Role
Director
Holding change
-17.2%
Trade date
Nov 11, 2026
4:55 PM ET Form 4
Insider Selling Vital Farms, Inc. VITL

Vital Farms 10% Owner Matthew Ohayer Sells $222K of Stock

Matthew Ohayer, 10% Owner, sold 23,250 shares of Vital Farms, Inc. at $9.56 a share, worth $222K in total on Nov 11, 2026. Shares held after the trade: 6,238,720 (-0.4%).

Value
$222K
Shares
23,250
Price
$9.56
Role
10% Owner
Holding change
-0.4%
Trade date
Nov 11, 2026
4:55 PM ET 10-Q
Financial Results Blue Line Holdings, Inc. BLNH

Blue Line Holdings Q1 2026 Results: Net Loss of $12.5K, Loss Widens

Blue Line Holdings, Inc. remains a pre-revenue industrial company with a net loss of $12,459 for the quarter ended September 30, 2026. The company reported a working capital deficit of $90,521 and expressed substantial doubt regarding its ability to continue as a going concern without additional financing.

Key figure
Net loss $12.5K
4:55 PM ET 8-K
Capital Raise Innovate Corp. VATE

Innovate Capital Raise

INNOVATE Corp. filed a prospectus supplement to establish a new $50 million at-the-market (ATM) equity offering program through Jefferies LLC. This program replaces a previous registration statement that expired in October 2026 and increases the potential offering amount from $31 million to $50 million. The filing also includes pro forma financial data reflecting the company's recent divestitures of its Broadcasting and DBM Global business units.

Counterparty
Jefferies LLC
4:55 PM ET 10-Q
Financial Results Inve Technologies, Inc. INVE

Inve Technologies Q3 2026 Results: Turns Profitable, Net Income $588K

For the quarter ended September 30, 2026, INVE Technologies reported a net income of $0.6 million, a significant improvement from a $3.5 million loss in the prior year, primarily driven by a $6.1 million gain on an asset sale. However, total revenue decreased to $3.1 million from $5.0 million year-over-year, and the company recorded a nine-month net loss of $7.5 million.

Key figure
Net income $588K
4:55 PM ET 10-Q
Financial Results Femasys Inc FEMY

Femasys Q3 2026 Results: Net Loss of $4.56M, Loss Widens

Femasys Inc. reported a decrease in sales for the nine months ended September 30, 2026, totaling $1,161,313 compared to $1,479,926 in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $23.9 million in cash and cash equivalents following financing activities, while maintaining an accumulated deficit of $154 million.

Key figure
Net loss $4.56M
4:55 PM ET 10-Q
Financial Results Edgemode, Inc. EDGM

Edgemode Q3 2026 Results: Net Loss of $1.37M

Edgemode, Inc. reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a loss of $14.4 million in the prior year period. The company's balance sheet shows a significant stockholders' deficit of $7.6 million and a substantial reduction in derivative liabilities from $15.4 million to $1.5 million during the year.

Key figure
Net loss $1.37M
4:55 PM ET 10-Q
Financial Results American Strategic Investment Co. NYC

American Strategic Investment Q3 2026 Results: Net Loss of $6.72M

American Strategic Investment Co. reported a net loss of $22.8 million for the nine months ended September 30, 2026, compared to a $14.5 million loss in the prior year. The company's total equity decreased to $47.3 million from $64.8 million at year-end 2025, primarily driven by the net loss and offset by common stock issuances to its Advisor.

Key figure
Net loss $6.72M
4:54 PM ET Form 4
Insider Selling 10x Genomics, Inc. TXG

10x Genomics CEO Serge Saxonov Sells $1.95M of Stock

Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).

Value
$1.95M
Shares
31,000
Price
$62.90
Role
CEO
Holding change
-3.0%
Trade date
Nov 10, 2026
4:53 PM ET 8-K
Other 8-K Filing Santander Holdings USA, Inc. SNUS-PH

Santander Holdings USA Other 8-K Filing

Santander Holdings USA, Inc. is recasting its historical financial statements for 2023, 2024, and 2025 to reflect changes in its internal management reporting structure. The company combined its Commercial & Industrial and Commercial Real Estate segments into a single Commercial Banking segment, and this filing provides the recast segment data for informational purposes without restating overall consolidated results.

4:53 PM ET 10-Q
Financial Results Hines Global Income Trust, Inc. HGIT

Hines Global Income Trust Q3 2026 Results: Net Loss of $21.3M, Loss Widens

This document is a formal consent from Altus Group U.S., Inc. allowing Hines Global Income Trust, Inc. to reference their role as an independent valuer in the company's Q3 2026 Quarterly Report. It specifically pertains to the valuation process described in the Net Asset Value section of the filing.

Key figure
Net loss $21.3M
4:52 PM ET 10-Q
Financial Results Origin Investment Corp I ORIQ

Origin Investment Corp I Q3 2026 Results: Net Income $391K, Up 1.9% YoY

Origin Investment Corp I reported a net income of $1,165,890 for the nine months ended September 30, 2026, primarily driven by $1,937,643 in interest income from its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and its total assets of $73.36 million are largely comprised of investments held in trust for a future business combination.

Key figure
Net income $391K · +1.9% YoY
4:52 PM ET 8-K
Financial Results Cerenome, Inc. CNSY

Cerenome Financial Results

Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.

Term
Q3 2026

“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”

Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
4:52 PM ET 10-Q
Financial Results Ckx Lands, Inc. CKX

Ckx Lands Q3 2026 Results: Net Income $444K, Up 167.0% YoY

CKX Lands, Inc. reported net income of $621,499 for the nine months ended September 30, 2026, an increase from $442,919 in the prior year period, driven largely by higher surface revenue and interest income. Total assets remained stable at approximately $22.4 million, while the company maintained a strong liquidity position with $15.9 million in cash and cash equivalents.

Key figure
Net income $444K · +167.0% YoY
4:52 PM ET 8-K
Financial Results Seritage Growth Properties SRG

Seritage Growth Properties Financial Results

Seritage Growth Properties reported Q3 2026 financial results, achieving net income of $2.7 million compared to a net loss for the nine-month period. The company generated $3.0 million from asset sales and received an $8.9 million distribution from an unconsolidated entity, while continuing to evaluate strategic options for its remaining portfolio.

Term
Q3 2026

“Although we have no new transactions under contract, we continue to work on both individual asset sales and potential strategic options for the portfolio and the Company”

Adam Metz, CEO & President
4:50 PM ET 8-K
Loan & Debt Apollo Global Management, Inc. APO

Apollo Global Management $600M Debt Financing with U.S. Bank Trust Company, National Association

Apollo Global Management issued $600 million in 7.550% Fixed-Rate Resettable Junior Subordinated Notes due 2056. The notes were issued under an indenture with U.S. Bank Trust Company as trustee and will bear a fixed rate until 2036, after which the rate will reset based on the Five-Year U.S. Treasury Rate plus a spread. Proceeds will be used for general corporate purposes, including a previously announced investment in Mubadala Capital Asset Management.

Value
$600M
Counterparty
U.S. Bank Trust Company, National Association
Term
30 years
4:50 PM ET 10-Q
Financial Results Grown Rogue International Inc. GRUSF

Grown Rogue International Q3 2026 Results: Net Loss of $8.89M

Grown Rogue International Inc. reported total revenue of $31.45 million for the nine months ended September 30, 2026, compared to $23.67 million in the prior year period. The company experienced a net loss of $12.58 million for the nine-month period, primarily driven by a $5.03 million loss on the acquisition of Rogue EBC and significant increases in general and administrative expenses.

Key figure
Net loss $8.89M
4:49 PM ET 8-K
Financial Results American Strategic Investment Co. NYC

American Strategic Investment Financial Results

American Strategic Investment Co. reported third quarter 2026 revenue of $7.1 million and a net loss of $6.7 million. The results reflect a decrease in revenue compared to the prior year due to the disposition of the 1140 Avenue of the Americas property. Subsequent to the quarter, the company signed a major lease extension and expansion with the State of New York at its 123 William Street property.

“The Company’s results this quarter build on the progress we made over the last two quarters, as our capital prioritization strategy continues to contribute to our results. The portfolio’s high quality, largely investment grade tenant base continues to support stable performance this year.”

Nicholas Schorsch, Jr., CEO of ASIC

“We remain focused on completing our remaining asset dispositions and directing capital toward the opportunities we believe will create the most durable value for our shareholders, such as the execution of the lease with the State of New York after the end of the quarter that increases pro-forma occupancy at 123 William Street to approximately 75% and portfolio occupancy to approximately 78%.”

Nicholas Schorsch, Jr., CEO of ASIC
4:49 PM ET Form 4
Insider Selling Nebius Group N.V. NBIS

Nebius Group Chief Revenue Officer Marc Boroditsky Sells $1.04M of Stock

Marc Boroditsky, Chief Revenue Officer, sold 7,000 shares of Nebius Group N.V. at $147.97 a share, worth $1.04M in total on Nov 11, 2026. Shares held after the trade: 0 (-100.0%).

Value
$1.04M
Shares
7,000
Price
$147.97
Role
Chief Revenue Officer
Holding change
-100.0%
Trade date
Nov 11, 2026
4:49 PM ET 8-K
M&A Deal Hall Chadwick Acquisition Corp HCAC

Hall Chadwick Acquisition Signs $400M M&A Deal with REEcycle Holdings, Inc.

Hall Chadwick Acquisition Corp. (HCAC) announced that the SEC has declared effective its Form S-4 registration statement for its proposed $400 million business combination with REEcycle Holdings, Inc. A shareholder meeting to vote on the merger is scheduled for December 10, 2026, with the deal expected to close by year-end. Upon completion, REEcycle will become a Nasdaq-listed company focused on domestic rare-earth element recycling technology.

Value
$400M
Counterparty
REEcycle Holdings, Inc.
4:49 PM ET 8-K
Loan & Debt Qualcomm Inc QCOM

Qualcomm $4B Debt Financing with U.S. Bank Trust Company, National Association

Qualcomm Incorporated executed an Officers' Certificate for the issuance and sale of $4.0 billion in aggregate principal amount of senior unsecured notes across five tranches maturing between 2028 and 2036. The notes carry interest rates ranging from 5.000% to 5.800% and rank equally with the company's other senior debt. The offering was conducted through an underwriting agreement with a syndicate of banks including BNP Paribas, BofA Securities, and J.P. Morgan.

Value
$4B
Counterparty
U.S. Bank Trust Company, National Association
Term
through Nov 2036
4:48 PM ET 8-K
Financial Results Femasys Inc FEMY

Femasys Financial Results

Femasys reported financial results for the third quarter of 2026, highlighting a slight increase in U.S. sales to $0.35 million despite overall sales declining due to international distributor order timing. The company completed a $30 million private placement in August to fund the build-out of its U.S. commercial team and support the FemBloc pivotal trial.

Term
Q3 2026

“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer

“These results and commercial recruitment progress give us strong confidence that deploying our team in target U.S. territories will broaden adoption and drive revenue growth.”

Kathy Lee-Sepsick, Founder and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.